BioIVT has acquired BeCytes Biotechnologies for an undisclosed amount, a corporate transaction that significantly expands BioIVT's portfolio in primary research cells and human tissue solutions. This move represents an acquisition where one company has bought another, and is not a funding round for either entity.
BeCytes Biotechnologies specializes in providing life science researchers with a diverse range of solutions tailored to preclinical research and human health improvement. Their offerings include an extensive portfolio of fresh, cryopreserved, and plateable human and animal primary hepatic cells, alongside comprehensive human tissue sourcing capabilities for research. Additionally, BeCytes provides preclinical contract research organization (CRO) services, offering scientific guidance and investigations for the validation of novel technologies and healthcare items. BeCytes serves a global clientele of pharmaceutical and biotechnology companies, academic institutions, and other contract research organizations.
This acquisition is strategically important for BioIVT, as it significantly enhances its capacity to offer a more diverse and comprehensive range of high-quality research solutions for drug discovery and development. By integrating BeCytes' specialized expertise in primary hepatic cells and human tissue sourcing, BioIVT aims to strengthen its position in critical preclinical research areas, including ADME-Tox studies, drug metabolism, and disease modeling. The addition of BeCytes’ state-of-the-art technologies and capabilities for customized solutions is expected to create substantial operational and scientific synergies, allowing the combined entity to provide even more integrated and efficient services to its global clientele across pharmaceutical, biotechnology, and CRO sectors.
The integration of BeCytes Biotechnologies is anticipated to broaden the scope and depth of BioIVT’s research tools, ultimately empowering pharmaceutical and biotechnology companies to accelerate their preclinical research efforts. The combined entity is poised to deliver an expanded range of high-quality biological products and services, fostering innovation in human health and therapeutic development.